Liraglutide: Difference between revisions

Line 20:

| intro = Liraglutide is a once-daily subcutaneous [[GLP-1 receptor agonist]] developed by Novo Nordisk and marketed as '''[[Victoza]]''' for [[type 2 diabetes mellitus]] (FDA-approved January 2010)<ref name="victoza-label"/> and as '''[[Saxenda]]''' at the higher 3.0 mg daily dose for [[obesity]] (December 2014).<ref name="saxenda-label"/>

Liraglutide was the first daily GLP-1 RA to reach market — preceded only by twice-daily exenatide (Byetta, 2005).<ref name="knudsen2000"/> It is the molecular predecessor and pharmacological template for [[semaglutide]], differing principally in the fatty-acid tail (C16 palmitic vs C18 fatty diacid) and the spacer architecture — semaglutide's modifications extending the half-life from ~13 h to ~165 h, enabling weekly rather than daily dosing.<ref name="lau2015">Lau J, Bloch P, Schäffer L et al. (2015). Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. ''J Med Chem'' 58(18):7370–80. doi:10.1021/acs.jmedchem.5b00726</ref>

Liraglutide was the first daily GLP-1 RA to reach market, preceded only by twice-daily exenatide (Byetta, 2005).<ref name="knudsen2000"/> It is the molecular predecessor and pharmacological template for [[semaglutide]], differing principally in the fatty-acid tail (C16 palmitic vs C18 fatty diacid) and the spacer architecture, semaglutide's modifications extending the half-life from ~13 h to ~165 h, enabling weekly rather than daily dosing.<ref name="lau2015">Lau J, Bloch P, Schäffer L et al. (2015). Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. ''J Med Chem'' 58(18):7370–80. doi:10.1021/acs.jmedchem.5b00726</ref>

Clinically, liraglutide is the first GLP-1 RA shown to reduce cardiovascular events in T2DM ([[LEADER trial|LEADER]]) and remains the only GLP-1 RA with formal pediatric approval — Victoza for T2DM in children ≥10 y, Saxenda for obesity in adolescents ≥12 y.<ref name="leader2016">Marso SP et al. (2016). Liraglutide and cardiovascular outcomes in type 2 diabetes (LEADER). ''NEJM'' 375:311–22. doi:10.1056/NEJMoa1603827</ref><ref name="victoza-label"/><ref name="saxenda-label"/>

Clinically, liraglutide is the first GLP-1 RA shown to reduce cardiovascular events in T2DM ([[LEADER trial|LEADER]]) and remains the only GLP-1 RA with formal pediatric approval, Victoza for T2DM in children ≥10 y, Saxenda for obesity in adolescents ≥12 y.<ref name="leader2016">Marso SP et al. (2016). Liraglutide and cardiovascular outcomes in type 2 diabetes (LEADER). ''NEJM'' 375:311–22. doi:10.1056/NEJMoa1603827</ref><ref name="victoza-label"/><ref name="saxenda-label"/>

| pharmacokinetics = '''Chemistry'''. 31-amino-acid acylated peptide analog of human [[GLP-1]] (7–37), with Arg34 substitution and a C16 palmitic acid linked via γGlu spacer at Lys26 — drives albumin binding for a ~13-hour half-life supporting once-daily dosing.<ref name="knudsen2000">Knudsen LB, Nielsen PF, Huusfeldt PO et al. (2000). Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. ''J Med Chem'' 43(9):1664–9. doi:10.1021/jm9909645</ref>

| pharmacokinetics = '''Chemistry'''. 31-amino-acid acylated peptide analog of human [[GLP-1]] (7–37), with Arg34 substitution and a C16 palmitic acid linked via γGlu spacer at Lys26, drives albumin binding for a ~13-hour half-life supporting once-daily dosing.<ref name="knudsen2000">Knudsen LB, Nielsen PF, Huusfeldt PO et al. (2000). Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. ''J Med Chem'' 43(9):1664–9. doi:10.1021/jm9909645</ref>

The C16 fatty acid drives non-covalent albumin binding (~98%), protecting from DPP-4 cleavage and slowing renal clearance — terminal half-life ~13 hours, supporting once-daily dosing.<ref name="knudsen2000"/><ref name="victoza-label"/> Cleared by proteolytic catabolism; no CYP-mediated metabolism. No dose adjustment for renal or hepatic impairment.<ref name="victoza-label"/>

The C16 fatty acid drives non-covalent albumin binding (~98%), protecting from DPP-4 cleavage and slowing renal clearance, terminal half-life ~13 hours, supporting once-daily dosing.<ref name="knudsen2000"/><ref name="victoza-label"/> Cleared by proteolytic catabolism; no CYP-mediated metabolism. No dose adjustment for renal or hepatic impairment.<ref name="victoza-label"/>

| pharmacodynamics = '''Receptor pharmacology'''. Selective agonist of the [[GLP-1 receptor]]. Produces glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, hypothalamic appetite suppression, and cardiovascular benefits independent of glycemia.<ref name="drucker2022">Drucker DJ (2022). GLP-1 physiology informs the pharmacotherapy of obesity. ''Mol Metab'' 57:101351.</ref>

Line 40:

| dosing = <titration slug="victoza-standard" author="MDElliottMD" title="Victoza — standard T2DM titration">

| dosing = <titration slug="victoza-standard" author="MDElliottMD" title="Victoza, standard T2DM titration">

0.6 mg SC daily × 1 week (tolerability ramp; not therapeutic)

→ 1.2 mg SC daily (typical maintenance)

Line 48:

</titration>

0.6 mg SC daily × 1 week

→ 1.2 mg × 1 week

Line 58:

</titration>

| effects = * '''Nausea''' — dose-dependent, worst in the first 1–2 weeks of any new dose level<ref name="victoza-label"/>

| effects = * '''Nausea''', dose-dependent, worst in the first 1–2 weeks of any new dose level<ref name="victoza-label"/>

* '''Diarrhea / constipation''' (variable)<ref name="victoza-label"/>

* '''Decreased appetite''' (the desired effect)<ref name="victoza-label"/>

* '''Early satiety'''<ref name="saxenda-label"/>

* '''Injection-site reactions''' — uncommon, generally mild<ref name="victoza-label"/>

* '''Injection-site reactions''', uncommon, generally mild<ref name="victoza-label"/>

* '''Headache''' (more common than with the weekly agents){{Citation needed}}

Line 69:

| interactions = <pharmaInteractions/>

| pregnancy_details = Avoid. Animal embryofetal toxicity is documented.<ref name="victoza-label"/> Discontinue before planned conception (the 13-hour half-life means washout is rapid — days, not weeks).

| pregnancy_details = Avoid. Animal embryofetal toxicity is documented.<ref name="victoza-label"/> Discontinue before planned conception (the 13-hour half-life means washout is rapid, days, not weeks).

| monitoring = * Baseline: HbA1c, weight, BP, renal function, lipid panel

* Personal or family history of MTC or [[MEN2]] — '''contraindicated''', do not start<ref name="victoza-label"/>

* Personal or family history of MTC or [[MEN2]], '''contraindicated''', do not start<ref name="victoza-label"/>

* Every 3 months for first year: HbA1c, weight, GI tolerability, signs of [[pancreatitis]] or [[gallbladder disease]]

* '''Pre-procedure''': skip the morning dose on the day of a planned procedure (per [[American Society of Anesthesiologists|ASA]] 2024 guidance for daily-dosed GLP-1 RAs)<ref name="kindel2024">Kindel TL et al. (2024). Perioperative GLP-1 receptor agonist safety guidance. ''Surg Obes Relat Dis'' 20(12):1183–8.</ref>

| counseling = * Daily injection same time each day — pick a time you can stick with.<ref name="victoza-label"/>

| counseling = * Daily injection same time each day, pick a time you can stick with.<ref name="victoza-label"/>

* GI side effects peak in first 1–2 weeks of each new dose level, then attenuate.

* If a daily dose is missed and remembered within ~12 h, take it; otherwise skip and resume the next day. Do not double-dose.<ref name="victoza-label"/>

MDElliottMD (talk | contribs)